Colorectal Cancer, Colorectal Cancer Metastatic, Lung Metastases
Conditions
Keywords
IVLP, metastatic
Brief summary
This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP technique has been used recently in a Phase I study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. The purpose of this study is to test the safety of the IVLP technique and find the dose that seems right in humans. Participants are given oxaliplatin into one lung via IVLP and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. Participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.
Interventions
DRUGOxaliplatin
Oxaliplatin infusion in single lung via IVLP technique
Sponsors
University Health Network, Toronto
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of Colorectal Carcinoma 2. Presence of bilateral pulmonary metastases 3. 3 or more lung lesions in total 4. Age 70 years or less 5. ECOG 0-2 6. Absence of extra-pulmonary disease, except liver metastases suitable to curative treatment.
Exclusion criteria
1. Patient has previously received more than 1000 mg of oxaliplatin 2. Left Ventricular Ejection Fraction \<50% 3. History of significant pulmonary disease or pneumonitis 4. Pregnant or lactating females 5. Age 71 or older, or less than 18 years 6. Inability to understand the informed consent process 7. Hypersenstivity to oxaliplatin 8. Patients with Heparin-induced thrombocytopenia (HIT) 9. Patients who cannot receive cefazolin or methylprednisolone due to allergy or another reason can be included but will not receive the drug they cannot tolerate 10. Current participation in another therapeutic clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety as measured by acute lung injury findings | 72 hours | Chest x- ray findings of pulmonary edema in the perfused lung in the first 72 hours (Grade 0-5). |
Secondary
| Measure | Time frame |
|---|---|
| recurrence patterns | 5 years |
| Incidence of pneumonia after procedure | 72 hours |
| Incidence of ICU admission | 72 hours |
| Incidence of mechanical ventilation | 72 hours |
Countries
Canada
Contacts
CONTACTJennifer K Lister
PRINCIPAL_INVESTIGATORMarcelo K Cypel, MD
University Health Network, Toronto
Outcome results
None listed